Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells

Weisberg, Ellen; Liu, Qingsong; Zhang, Xin; Nelson, Erik; Sattler, Martin; Liu, Feiyang; Nicolais, Maria; Zhang, Jianming; Mitsiades, Constantine; Smith, Robert W.; Stone, Richard; Galinsky, Ilene; Nonami, Atsushi; Griffin, James D.; Gray, Nathanael
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Objectives: Tyrosine kinase inhibitor (TKI)-treated acute myeloid leukemia (AML) patients commonly show rapid and significant peripheral blood blast cell reduction, however a marginal decrease in bone marrow blasts. This suggests a protective environment and highlights the demand for a better understanding of stromal:leukemia cell communication. As a strategy to improve clinical efficacy, we searched for novel agents capable of potentiating the stroma-diminished effects of TKI treatment of mutant FLT3-expressing cells. Methods: We designed a combinatorial high throughput drug screen using well-characterized kinase inhibitor-focused libraries to identify novel kinase inhibitors capable of overriding stromal-mediated resistance to TKIs, such as PKC412 and AC220. Standard liquid culture proliferation assays, cell cycle and apoptosis analysis, and immunoblotting were carried out with cell lines or primary AML to validate putative candidates from the screen and characterize the mechanism(s) underlying observed synergy. Results and Conclusions: Our study led to the observation of synergy between selective Akt inhibitors and FLT3 inhibitors against mutant FLT3-positive AML in either the absence or presence of stroma. Our findings are consistent with evidence that Akt activation is characteristic of mutant FLT3-transformed cells, as well as observed residual Akt activity following FLT3 inhibitor treatment. In conclusion, our study highlights the potential importance of Akt as a signaling factor in leukemia survival, and supports the use of the co-culture chemical screen to identify agents able to potentiate TKI anti-leukemia activity in a cytoprotective microenvironment.


Related Articles

  • Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor. Lou, Yin-jun // Acta Pharmacologica Sinica;Feb2012, Vol. 33 Issue 2, p212 

    No abstract available.

  • Frequent loss of RAF kinase inhibitor protein expression in acute myeloid leukemia. Zebisch, A; Wölfler, A; Fried, I; Wolf, O; Lind, K; Bodner, C; Haller, M; Drasche, A; Pirkebner, D; Matallanas, D; Rath, O; Blyth, K; Delwel, R; Taskesen, E; Quehenberger, F; Kolch, W; Troppmair, J; Sill, H // Leukemia (08876924);Aug2012, Vol. 26 Issue 8, p1842 

    RAF kinase inhibitor protein (RKIP) is a negative regulator of the RAS-mitogen-activated protein kinase/extracellular signal-regulated kinase signaling cascade. We investigated its role in acute myeloid leukemia (AML), an aggressive malignancy arising from hematopoietic stem and progenitor cells...

  • Cellular Intrinsic Mechanism Affecting the Outcome of AML Treated with Ara-C in a Syngeneic Mouse Model. Zhao, Wenjun; Wei, Lirong; Tan, Dongming; Su, Guangsong; Zheng, Yanwen; He, Chao; Mao, Zhengwei J.; Singleton, Timothy P.; Yin, Bin // PLoS ONE;Oct2014, Vol. 9 Issue 10, p1 

    The mechanisms underlying acute myeloid leukemia (AML) treatment failure are not clear. Here, we established a mouse model of AML by syngeneic transplantation of BXH-2 derived myeloid leukemic cells and developed an efficacious Ara-C-based regimen for treatment of these mice. We proved that...

  • Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells. Weisberg, Ellen; Ray, Arghya; Nelson, Erik; Adamia, Sophia; Barrett, Rosemary; Sattler, Martin; Zhang, Chengsheng; Daley, John F.; Frank, David; Fox, Edward; Griffin, James D. // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Objectives: Clinical responses achieved with FLT3 kinase inhibitors in acute myeloid leukemia (AML) are typically transient and partial. Thus, there is a need for identification of molecular mechanisms of clinical resistance to these drugs. In response, we characterized MOLM13 AML cell lines...

  • Effector mechanisms of sunitinib-induced G1 cell cycle arrest, differentiation, and apoptosis in human acute myeloid leukaemia HL60 and KG-1 cells. Teng, Chieh-Lin; Yu, Chang-Tze; Hwang, Wen-Li; Tsai, Jia-Rong; Liu, Hsiang-Chun; Hwang, Guang-Yuh; Hsu, Shih-Lan // Annals of Hematology;Mar2013, Vol. 92 Issue 3, p301 

    Acute myeloid leukaemia (AML) is a heterogeneous disease with dismal outcome. Sunitinib is an orally active inhibitor of multiple tyrosine kinase receptors approved for renal cell carcinoma and gastrointestinal stromal tumour that has also been studied for AML in several clinical trials....

  • WTAP is a novel oncogenic protein in acute myeloid leukemia. Bansal, H; Yihua, Q; Iyer, S P; Ganapathy, S; Proia, D; Penalva, L O; Uren, P J; Suresh, U; Carew, J S; Karnad, A B; Weitman, S; Tomlinson, G E; Rao, M K; Kornblau, S M; Bansal, S // Leukemia (08876924);May2014, Vol. 28 Issue 5, p1171 

    The article presents a study on the role of WTAP as a high conserved protein in acute myelogenous leukemia (AML) that partners with Wilms' tumor 1 (WT1) gene to function as a switch gene to regulate the balance between quiescence and proliferation. It notes the above normal levels of WTAP...

  • Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. François, Rony A.; Maeng, Kyungah; Nawab, Akbar; Kaye, Frederic J.; Hochwald, Steven N.; Zajac-Kaye, Maria // JNCI: Journal of the National Cancer Institute;Aug2015, Vol. 107 Issue 8, p1 

    Background: Focal adhesion kinase (FAK) mediates survival of normal pancreatic islets through activation of AKT. Upon malignant transformation of islet cells into pancreatic neuroendocrine tumors (PanNETs), AKT is frequently overexpressed and mutations in the AKT/mTOR pathway are detected....

  • JNK-Mediated FOXO Expression Plays a Critical Role in EGFR Tyrosine Kinase Inhibitor-Induced BIM Expression and Apoptosis. Takeuchi, Kenji; Viet, Anh Ho; Kawasaki, Katsumi; Nishio, Kazuto; Ito, Fumiaki // Journal of Cancer Therapy;Aug2012 Supplement, Vol. 3 Issue 4A, p424 

    BIM, a key pro-apoptotic member of the BCL-2 family of proteins, is essential for apoptosis triggered by tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR). However, the precise molecular mechanism by which EGFR-TKIs induce BIM expression has remained unclear. A...

  • CD44 targets Wnt/beta-catenin pathway to mediate the proliferation of K562 cells. Guoqiang Chang; Hongju Zhang; Jian Wang; Yujuan Zhang; Hua Xu; Chijuan Wang; Hairui Zhang; Li Ma; Qinghua Li; Tianxiang Pang // Cancer Cell International;2013, Vol. 13 Issue 1, p1 

    Background Chronic myeloid leukemia is a clonal myeloproliferative disorder disease in which BCR/ABL plays an important role as an oncoprotein and molecular target. Despite the success of targeted therapy using tyrosine kinase inhibitors, CML remains largely incurable, most likely due to the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics